TKI plus chemo and CAR-T for newly diagnosed Ph+ ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests combining a targeted drug (TKI) with chemotherapy and then CAR-T cells for adults who are newly diagnosed with Philadelphia chromosome-positive ALL. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are aged 18 or older.
- You have been newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (a type of blood cancer with a specific gene change).
- Your leukemia cells show a protein called CD19, which the CAR-T cells target.
- Your major organs like heart, liver, kidneys, and pancreas are working well enough (doctors will check with blood tests and heart ultrasound).
- You have not already received treatment for your ALL (except for very limited pre-treatment).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy together with a special immune cell treatment called CAR-T cells for adults who have just been diagnosed with a specific type of leukemia (Ph- B-ALL). The goal is to see if this combination works better than standard treatment.
This trial combines a targeted antibody therapy with a low dose of chemotherapy to treat adults newly diagnosed with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). The goal is to see if this combo can help shrink or eliminate the leukemia with fewer side effects than standard treatment.
This trial tests a combination of chemotherapy and targeted immunotherapy for people with a specific type of leukemia (Ph+ ALL) that has not been treated before. The goal is to see if this approach can help control the disease better.
This trial tests a combination of targeted drugs (ABL/JAK inhibitors) with chemotherapy and venetoclax for people with a type of leukemia called Ph-like ALL. It aims to see if this treatment is safe and effective.
This trial tests a CD19-targeted CAR-T cell therapy (S1904) for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. After CAR-T, some patients may go on to a stem cell transplant. The goal is to see if the CAR-T can lead to remission and who needs a transplant.
This trial tests a CAR-T cell therapy for adults who have just been diagnosed with a type of leukemia called Ph+ B-cell ALL. The treatment uses specially engineered immune cells to target and destroy cancer cells that have a specific marker (CD19 and CD22) and the Philadelphia chromosome. It may be an option for those who have not yet started standard chemotherapy.
Hear when a new Acute Lymphoblastic Leukemia, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.